The EGFR and HER2 inhibitor TAK-788 has antitumor activity against non-small-cell lung cancer with EGFR exon 20 insertions, according to phase I/II findings reported at the 2019 ASCO Annual Meeting.
Men with metastatic castration-sensitive prostate cancer derive a significant overall survival benefit from the addition of enzalutamide to standard testosterone suppression, show phase III trial results.
Phase I data indicate that the selective RET inhibitor BLU-667 elicits durable responses and is well tolerated by individuals with advanced non-small-cell lung cancer harboring a RET fusion.
Combining erlotinib with ramucirumab significantly improves the progression-free survival of untreated patients with advanced EGFR mutation-positive non-small-cell lung cancer, suggest phase III results presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.
Research presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, adds support for use of pembrolizumab plus axitinib as a first-line treatment for patients with metastatic renal cell carcinoma.
Updated results from the phase Ib KEYNOTE-001 trial suggest that some individuals with advanced non-small-cell lung cancer can achieve long-term survival with pembrolizumab monotherapy.